Printer Friendly

Lynparza phase III trial indicates decreased risk of disease progression or death in BRCA-mutated ovarian cancer patients.

M2 PHARMA-October 23, 2018-Lynparza phase III trial indicates decreased risk of disease progression or death in BRCA-mutated ovarian cancer patients

(C)2018 M2 COMMUNICATIONS

A phase III trial has indicated that Lynparza maintenance therapy decreased risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated (BRACm) ovarian cancer, it was reported on Monday.

The Phase III SOLO-one trial evaluated the product as a maintenance treatment for patients with newly-diagnosed and advanced BRCA-mutated (BRCAm) ovarian cancer, who have been in complete or partial response following first-line standard platinum-based chemotherapy. The study indicated statistically-significant and clinically-meaningful improvement in progression-free survival for Lynparza compared with placebo and reduced the risk of disease progression or death by 70%.

The product is being jointly developed and commercialised by AstraZeneca and Merck. At present, Lynparza secured approval in more than 60 countries to treat platinum-sensitive relapsed ovarian cancer regardless of BRCA status.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 23, 2018
Words:161
Previous Article:Vertex Pharmaceuticals (Europe) receives positive opinion from European watchdog for Kalydeco.
Next Article:Teva Formalises North America Headquarters Move with Ceremony in Israel.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters